Clinical Trial Update: XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports completion of Phase 1/2 trials evaluating XIAP antisense AEG35156 in combination with sorafenib for advanced hepatocellular c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AEG35156 (XIAP antisense oligonucleotide) (AEG35156)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Aegera Therapeutics | Conditions: Advanced Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: COMPLETED